Additional Study Information: The purpose of this study is to see if a new medication called ticagrelor given twice daily ismore effective than aspirin alone in preventing the occurrence of heart attack, stroke and/ordeath due to cardiovascular events in patients who have type 2 diabetes. Ticagrelor is anantiplatelet therapy (stop platelets from clumping together) and is approved for sale by theU.S. Food and Drug Administration (FDA). The study will explore if ticagrelor in addition toother recommended treatments, can further reduce the risk for cardiovascular events.